OPK - OPKO Health Inc Stock Price, Fair Value and News

1.23USD-0.02 (-1.60%)Market Closed

Market Summary

USD1.23-0.02

Market Closed

-1.60%

OPK Alerts

1 major insider buys recently.

OPK Stock Price

View Fullscreen

OPK RSI Chart

OPK Valuation

Market Cap

857.3M

Price/Earnings (Trailing)

-4.54

Price/Sales (Trailing)

0.99

EV/EBITDA

-11.75

Price/Free Cashflow

-30.4

OPK Price/Sales (Trailing)

OPK Profitability

EBT Margin

-21.35%

Return on Equity

-13.59%

Return on Assets

-9.39%

Free Cashflow Yield

-3.29%

OPK Fundamentals

OPK Revenue

Revenue (TTM)

863.5M

Rev. Growth (Yr)

-1.85%

Rev. Growth (Qtr)

1.85%

OPK Earnings

Earnings (TTM)

-188.9M

Earnings Growth (Yr)

22%

Earnings Growth (Qtr)

21.3%

Breaking Down OPK Revenue

Last 7 days

3.3%

Last 30 days

30.2%

Last 90 days

25%

Trailing 12 Months

-14.4%

How does OPK drawdown profile look like?

OPK Financial Health

Current Ratio

1.55

Debt/Equity

0.01

Debt/Cashflow

-3.65

OPK Investor Care

Buy Backs (1Y)

9.79%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	912.6M	868.1M	866.9M	863.5M
2022	1.6B	1.4B	1.2B	1.0B
2021	1.8B	1.9B	1.9B	1.8B
2020	891.0M	965.8M	1.2B	1.4B
2019	957.8M	920.5M	899.4M	901.9M
2018	954.5M	925.6M	929.4M	990.3M
2017	1.1B	1.1B	1.1B	966.0M
2016	730.6M	1.0B	1.1B	1.1B
2015	98.9M	117.8M	241.1M	491.7M
2014	87.4M	87.2M	86.3M	91.1M
2013	69.6M	83.3M	92.1M	96.5M
2012	29.8M	31.6M	36.6M	47.0M
2011	32.3M	33.3M	34.4M	28.0M
2010	0	12.4M	20.5M	28.5M
2009	0	0	0	4.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of OPKO Health Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 18, 2024	frost phillip md et al	bought	437,100	0.8742	500,000	ceo & chairman
Mar 14, 2024	frost phillip md et al	bought	444,300	0.8886	500,000	ceo & chairman
Mar 13, 2024	frost phillip md et al	bought	463,750	0.9275	500,000	ceo & chairman
Mar 12, 2024	frost phillip md et al	bought	559,380	0.9323	600,000	ceo & chairman
Feb 28, 2024	frost phillip md et al	bought	496,150	0.9923	500,000	ceo & chairman
Feb 21, 2024	frost phillip md et al	bought	991,700	0.9917	1,000,000	ceo & chairman
Feb 07, 2024	frost phillip md et al	bought	1,462,800	0.9752	1,500,000	ceo & chairman
Jan 29, 2024	krasno richard m	bought	29,838	0.9946	30,000	-
Jan 19, 2024	frost phillip md et al	bought	488,650	0.9773	500,000	ceo & chairman
Jan 18, 2024	frost phillip md et al	bought	386,200	0.9655	400,000	ceo & chairman

Which funds bought or sold OPK recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	Tennessee Valley Asset Management Partners	sold off	-	-	-	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-60.94	-36,000	17,000	-%
Apr 23, 2024	WETZEL INVESTMENT ADVISORS, INC.	unchanged	-	-508	492	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	-19,022	319,135	-%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	reduced	-1.8	-12,919	45,918	-%
Apr 22, 2024	PFG Investments, LLC	new	-	1,124,720	1,124,720	0.07%
Apr 22, 2024	PROFESSIONAL ADVISORY SERVICES INC	new	-	12,000	12,000	-%
Apr 22, 2024	Raymond James Financial Services Advisors, Inc.	added	6.52	-12,019	66,281	-%
Apr 19, 2024	Kovack Advisors, Inc.	new	-	12,000	12,000	-%
Apr 18, 2024	Northstar Group, Inc.	unchanged	-	-8,613	33,342	0.01%

Are Funds Buying or Selling OPK?

Are funds buying OPK calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own OPK

No. of Funds

OPK Alerts

1 major insider buys recently.

Unveiling OPKO Health Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	5.14%	39,751,293	SC 13G/A
Jan 24, 2024	frost phillip md et al	-	8	SC 13D/A
Jan 24, 2024	hsiao jane ph d	-	11	SC 13D/A
Jan 22, 2024	frost phillip md et al	-	8	SC 13D/A
Feb 21, 2023	frost phillip md et al	27.2%	213,891,935	SC 13D/A
Feb 09, 2023	vanguard group inc	5.32%	41,120,494	SC 13G/A
Aug 19, 2022	frost phillip md et al	26.0%	202,156,694	SC 13D/A
Aug 19, 2022	hsiao jane ph d	0.7%	5,127,404	SC 13D/A
Jun 29, 2022	zerhouni elias a.	2.9%	19,867,114	SC 13D
Jun 29, 2022	nabel gary j.	2.9%	20,012,985	SC 13D

Recent SEC filings of OPKO Health Inc

View All Filings

Date Filed	Form Type	Document
Mar 29, 2024	4	Insider Trading
Mar 29, 2024	4	Insider Trading
Mar 29, 2024	4	Insider Trading
Mar 29, 2024	4	Insider Trading
Mar 29, 2024	4	Insider Trading
Mar 29, 2024	4	Insider Trading
Mar 29, 2024	8-K	Current Report
Mar 28, 2024	8-K	Current Report
Mar 28, 2024	8-K/A	Current Report
Mar 18, 2024	4	Insider Trading

Peers (Alternatives to OPKO Health Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	174.4B	23.7B	-0.66%	-0.48%	39.62	7.35	-8.94%	-35.72%
IDXX	41.1B	3.7B	-6.96%	-1.95%	48.61	11.22	8.72%	24.44%
A	40.3B	6.7B	-5.62%	0.50%	32.59	5.98	-2.81%	-6.58%
DGX	15.2B	9.3B	5.76%	-6.69%	17.84	1.65	-6.38%	-9.73%
CRL	12.3B	4.1B	-11.91%	17.80%	25.9	2.98	3.86%	-2.39%
MEDP	11.5B	2.0B	-0.40%	117.42%	36.88	5.87	25.57%	21.62%
EXAS	11.5B	2.5B	2.30%	-4.05%	-56.23	4.59	19.93%	67.26%
NTRA	11.0B	1.1B	-1.39%	71.77%	-25.41	10.21	31.99%	20.63%
MID-CAP
NEOG	2.7B	929.2M	-19.07%	-29.09%	1.7K	2.87	28.93%	111.61%
GH	2.2B	563.9M	0.58%	-24.79%	-4.59	3.91	25.45%	26.76%
SMALL-CAP
CDNA	413.2M	280.3M	-13.73%	-2.49%	-2.17	1.47	-12.89%	-148.37%
ACRS	83.0M	31.2M	6.09%	-86.56%	-0.94	2.66	5.03%	-1.81%
AWH	41.8M	9.2M	-7.12%	-37.22%	-2.51	4.57	11.85%	44.12%
APDN	4.9M	9.0M	-42.00%	-72.12%	-0.68	0.55	-53.31%	2.21%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

OPKO Health Inc News

Latest updates

OPKO Health Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	1.9%	181,905,000	178,595,000	265,418,000	237,577,000	185,340,000	179,744,000	309,893,000	329,219,000	401,332,000	385,813,000	442,408,000	545,165,000	494,676,000	428,064,000	301,207,000	211,466,000	224,344,000	228,772,000	226,368,000	222,451,000	221,852,000
Operating Expenses	3.3%	250,949,000	243,002,000	258,393,000	268,171,000	240,610,000	267,564,000	320,632,000	401,643,000	464,416,000	347,987,000	436,837,000	506,728,000	445,318,000	406,125,000	274,028,000	252,228,000	336,807,000	267,783,000	273,628,000	297,769,000	311,866,000
S&GA Expenses	0.9%	72,883,000	72,240,000	79,794,000	75,642,000	73,997,000	79,674,000	101,464,000	117,537,000	138,214,500	105,120,000	113,236,000	112,286,000	101,823,500	99,897,000	77,721,000	76,132,000	79,130,000	80,542,000	88,475,000	95,158,000	95,103,500
R&D Expenses	-0.2%	19,394,000	19,435,000	18,159,000	32,605,000	19,528,500	18,792,000	17,254,000	18,312,000	21,007,000	18,306,000	18,222,000	19,315,000	17,454,500	18,493,000	17,608,000	21,760,000	23,038,000	30,017,000	28,286,000	36,529,000	33,328,000
EBITDA Margin	32.3%	-0.08	-0.11	-0.16	-0.22	-0.27	-0.20	-0.07	-0.02	0.04	0.10	0.09	0.13	-	-	-	-	-	-	-	-	-
Interest Expenses	-4.4%	3,234,000	3,384,000	3,277,000	3,830,000	2,923,000	3,017,000	3,075,000	3,420,000	10,494,000	3,503,000	194,000	4,689,000	251,000	5,079,000	566,000	5,012,000	789,000	5,673,000	4,900,000	511,000	445,000
Income Taxes	-199.1%	-6,019,000	6,075,000	3,148,000	1,233,000	-16,975,500	-40,327,000	15,070,000	-21,266,000	7,495,500	2,680,000	4,754,000	560,000	13,596,000	-3,178,000	6,028,000	1,171,000	3,424,000	1,769,000	1,084,000	783,000	-28,288,500
Earnings Before Taxes	7.5%	-72,494,000	-78,378,000	-16,450,000	-16,997,000	-102,183,000	-126,375,000	-86,312,000	-76,650,000	-65,812,500	31,472,000	-11,365,000	31,681,000	45,941,000	20,649,000	39,920,000	-57,827,000	-108,445,000	-59,944,000	-58,451,000	-78,125,000	-101,404,500
EBT Margin	10.4%	-0.21	-0.24	-0.28	-0.34	-0.39	-0.29	-0.14	-0.08	-0.01	0.05	0.05	0.08	-	-	-	-	-	-	-	-	-
Net Income	21.3%	-66,483,000	-84,473,000	-19,640,000	-18,267,000	-85,231,000	-86,091,000	-101,650,000	-55,433,000	-73,775,000	28,739,000	-16,186,000	31,078,000	32,298,000	23,717,000	33,703,000	-59,132,000	-112,350,000	-62,007,000	-59,806,000	-80,762,000	-76,070,000
Net Income Margin	5.3%	-0.22	-0.23	-0.22	-0.30	-0.33	-0.26	-0.14	-0.07	-0.02	0.04	0.04	0.07	-	-	-	-	-	-	-	-	-
Free Cashflow	-215.7%	-38,294,000	33,109,000	-365,000	-22,647,000	-31,620,000	-32,236,000	-11,477,000	-19,856,000	-5,643,000	33,395,000	-15,452,000	26,037,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-2.2%	2,012	2,057	2,159	2,170	2,167	2,225	2,370	2,307	2,400	2,418	2,422	2,520	2,473	2,371	2,324	2,233	2,309	2,370	2,456	2,575	2,451
Current Assets	-13.4%	309	357	434	406	395	414	495	754	823	558	547	599	523	428	360	274	324	293	344	435	318
Cash Equivalents	-30.8%	96.00	139	108	111	153	181	210	102	135	149	66.00	90.00	72.00	36.00	22.00	35.00	85.00	65.00	111	207	96.00
Inventory	-4.7%	66.00	69.00	74.00	75.00	74.00	71.00	83.00	99.00	87.00	113	135	159	132	112	73.00	59.00	53.00	50.00	48.00	45.00	42.00
Net PPE	-3.5%	75.00	78.00	79.00	-	83.00	-	-	-	-	-	-	139	141	134	131	127	127	129	137	140	145
Goodwill	0.6%	598	594	597	597	596	573	579	519	710	675	677	676	719	676	672	670	710	696	700	699	712
Liabilities	1.7%	622	612	624	618	606	596	651	692	715	652	679	823	802	748	735	684	695	728	747	813	660
Current Liabilities	-0.3%	200	201	226	222	213	267	215	309	330	283	304	404	375	336	280	245	249	270	283	396	288
Long Term Debt	-	8.00	-	-	-	9.00	-	-	-	-	2.00	4.00	3.00	4.00	4.00	4.00	4.00	4.00	4.00	5.00	4.00	5.00
LT Debt, Current	-	2.00	-	-	-	2.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6.00
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	2.00	4.00	3.00	4.00	4.00	4.00	4.00	4.00	4.00	5.00	4.00	5.00
Shareholder's Equity	-3.8%	1,389	1,445	1,535	1,552	1,562	1,629	1,719	1,615	1,685	1,766	1,743	1,697	1,672	1,624	1,588	1,549	1,615	1,642	1,709	1,763	1,791
Retained Earnings	-3.4%	-2,011	-1,945	-1,860	-1,841	-1,822	-1,737	-1,651	-1,549	-1,511	-1,438	-1,466	-1,450	-1,481	-1,514	-1,537	-1,571	-1,511	-1,398	-1,336	-1,276	-1,197
Additional Paid-In Capital	0.1%	3,433	3,430	3,427	3,425	3,422	3,419	3,414	3,191	3,222	3,219	3,214	3,156	3,153	3,150	3,147	3,145	3,143	3,065	3,062	3,059	3,004
Accumulated Depreciation	-	157	-	-	-	142	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	112
Shares Outstanding	0.0%	752	752	752	752	719	750	713	660	648	647	647	641	-	-	-	-	-	-	-	-	-
Float	-	-	-	904	-	-	-	1,061	-	-	-	1,607	-	-	-	1,362	-	-	-	867	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-215.7%	-38,294	33,109	-365	-22,647	-31,620	-32,236	-11,477	-19,856	-5,643	33,395	-15,452	26,037	34,258	63,011	-14,423	-43,370	-46,037	-23,866	-53,631	-48,988	-34,659
Share Based Compensation	-15.9%	2,690	3,200	2,800	2,700	3,193	3,400	4,300	7,617	3,671	3,822	3,460	2,647	2,123	2,740	1,586	2,451	2,393	3,428	3,122	4,457	5,170
Cashflow From Investing	60.3%	-1,418	-3,572	-5,491	-7,717	-7,872	-4,682	108,495	-4,903	-8,679	54,576	-8,842	-1,106	-6,744	5,501	-11,465	-5,619	-3,756	-2,191	-3,191	-4,132	-2,882
Cashflow From Financing	-278.2%	-3,751	2,105	3,462	-13,119	10,144	8,444	12,274	-7,891	833	-4,255	264	-7,192	8,108	-54,461	12,888	-1,611	70,644	-19,995	-39,276	163,875	90,704

OPK Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Revenues	$ 863,495	$ 1,004,196	$ 1,774,718
Costs and expenses:
Selling, general and administrative	300,559	372,672	468,857
Research and development	89,593	73,887	76,850
Contingent consideration	(1,036)	(1,312)	(1,703)
Amortization of intangible assets	86,032	87,784	50,278
Gain on sale of assets	0	(18,559)	(31,508)
Total costs and expenses	1,020,516	1,230,449	1,755,968
Operating income (loss)	(157,021)	(226,253)	18,750
Other income and (expense), net:
Interest income	3,983	1,981	28
Interest expense	(13,506)	(12,056)	(18,880)
Fair value changes of derivative instruments, net	(781)	649	846
Other income (expense), net	(16,994)	(155,842)	(14,769)
Other expense, net	(27,298)	(165,268)	(32,775)
Loss before income taxes and investment losses	(184,319)	(391,521)	(14,025)
Income tax benefit (provision)	(4,437)	63,499	(15,489)
Net loss before investment losses	(188,756)	(328,022)	(29,514)
Loss from investments in investees	(107)	(383)	(629)
Net loss	$ (188,863)	$ (328,405)	$ (30,143)
Loss per share basic and diluted:
Loss per share (in dollars per share)	$ (0.25)	$ (0.46)	$ (0.05)
Weighted average number of common shares outstanding, basic and diluted (in shares)	751,765,915	719,060,942	648,077,716
Service [Member]
Revenues:
Revenues	$ 515,275	$ 755,630	$ 1,607,106
Costs and expenses:
Cost of Goods and Services Sold	445,830	627,548	1,102,172
Product [Member]
Revenues:
Revenues	167,557	142,845	141,770
Costs and expenses:
Cost of Goods and Services Sold	99,538	88,429	91,022
Transfer of Intellectual Property and Other [Member]
Revenues:
Revenues	$ 180,663	$ 105,721	$ 25,842

OPK Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 95,881	$ 153,191
Accounts receivable, net	123,379	127,312
Inventory, net	65,697	74,060
Other current assets and prepaid expenses	24,519	39,962
Total current assets	309,476	394,525
Property, plant and equipment, net	75,429	82,879
Intangible assets, net	740,283	823,520
In-process research and development	195,000	195,000
Goodwill	598,260	595,851
Total carrying value of investments	16,082	28,080
Operating lease right-of-use assets	68,088	38,725
Other assets	9,080	8,679
Total assets	2,011,698	2,167,259
Current liabilities:
Accounts payable	69,677	66,993
Accrued expenses	90,086	98,269
Current maturities of operating leases	12,996	11,628
Current portion of convertible notes	0	3,050
Current portion of lines of credit and notes payable	27,293	33,540
Total current liabilities	200,052	213,480
Operating lease liabilities	54,140	27,963
Convertible notes	214,325	210,371
Deferred tax liabilities	126,773	126,426
Other long-term liabilities, principally contract liabilities, contingent consideration and lines of credit	27,189	27,371
Total long-term liabilities	422,427	392,131
Total liabilities	622,479	605,611
Equity:
Common Stock - $0.01 par value, 1,000,000,000 shares authorized; 781,936,885 and 781,306,164 shares issued at December 31, 2023 and 2022, respectively	7,820	7,813
Treasury Stock, - 8,655,082 shares at December 31, 2023 and 2022, respectively	(1,791)	(1,791)
Additional paid-in capital	3,433,006	3,421,872
Accumulated other comprehensive loss	(38,030)	(43,323)
Accumulated deficit	(2,011,786)	(1,822,923)
Total shareholders’ equity	1,389,219	1,561,648
Total liabilities and equity	$ 2,011,698	$ 2,167,259

About OPKO Health Inc

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

CEO	Dr. Phillip Frost Ph.D.
WEBSITE	opko.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	4196

OPKO Health Inc Frequently Asked Questions

What is the ticker symbol for OPKO Health Inc? What does OPK stand for in stocks?

OPK is the stock ticker symbol of OPKO Health Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of OPKO Health Inc (OPK)?

As of Tue Apr 23 2024, market cap of OPKO Health Inc is 871.24 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OPK stock?

You can check OPK's fair value in chart for subscribers.

What is the fair value of OPK stock?

You can check OPK's fair value in chart for subscribers. The fair value of OPKO Health Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of OPKO Health Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OPK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is OPKO Health Inc a good stock to buy?

The fair value guage provides a quick view whether OPK is over valued or under valued. Whether OPKO Health Inc is cheap or expensive depends on the assumptions which impact OPKO Health Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OPK.

What is OPKO Health Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, OPK's PE ratio (Price to Earnings) is -4.61 and Price to Sales (PS) ratio is 1.01. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OPK PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on OPKO Health Inc's stock?

In the past 10 years, OPKO Health Inc has provided -0.17 (multiply by 100 for percentage) rate of return.